Table 1.
Clinical trials using replicating and non-replicating adenoviral vectors for cancer therapy.
| No | Ad vector | Transgene | Cancer | Phase | Reference |
|---|---|---|---|---|---|
| 1 | ChAdOx1–MVA | STEAP1 | Prostate cancer | Preclinical | 195 |
| 2 | Ad-IFN/Syn 3 | INF-α | Bladder cancer | Preclinical trail | 124 |
| 3. | Ad5-yCD/mutTKSR39rep-hIL-12 | Cytosine deaminase, HSV-tK, hIL-12 | metastatic Prostate cancer | I | NCT03281382 |
| 4. | SCH-58500 | P53 | Primary ovarian cancer, fallopian cancer and peritoneal cancer | I | 200 |
| 5. | ONCOS-102 | GM-CSF | Melanoma | I | 127 |
| 6. | Adv-tk (GMCI) | Adv-tk | Pediatric brain tumors | I | 201 |
| 7 | Ad-RTS-hIL-12 | IL-12 | Glioblastoma or malignant glioma; Advanced or metastatic breast cancer; recurrent or progressive melanoma | I | 142 |
| 8 | Ad-E6E7 and MG1-E6E7 | HPV E6/E7 | HPV-associated cancer | I | 194 |
| 9 | TILT-123 | hTNF-α, hIL-2 | Advanced melanoma | I | 202 |
| 10 | ADV/RSV-TK | HSV-TK | prostate cancer; glioma, retinoblastoma, mesothelioma | I | 156–159 |
| 11 | BG00001 | INF-β | Pleural melanoma | I | |
| 12 | DNX-2440 | OX40L | Glioblastoma | I | NCT03714334 |
| 13 | Ad/PNP+ fludarabine | PNP | Head and neck squamous cell carcinoma | 1 | 203 |
| 14 | ETBX-011, ETBX-061, and ETBX-051 (Tri-Ad vaccine) | TAA | Advanced cancer | I | 187 |
| 15 | Ad5-yCD/mutTKSR39rep-hIL-12 | Cytosine deaminase, HSV-tK, IL-12 | Prostate cancer | I | NCT02555397 |
| 16 | Ad5-PSA | PSA | Prostate cancer; recurrent/hormone refractory prostate cancer | I/II | 189–191 |
| 17 | Advexin (rAd-p53) | P53 | squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx; colorectal cancer, HCC, NSCLC, prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioma, and squamous cell carcinoma of the head and neck | I/II | 92–95 |
| 18 | AdHSV-tk/GCV | HSV-tk Ad- hCMV- Flt3L | High-grade malignant gliomas | I/II | 204 |
| 19 | ETBX-011 | CEA | Metastatic colorectal cancer | I/II | 183–185 |
| 20 | Ad-MAGEA3 | MAGE-A3 | Advanced/Met., MAGE-A3+ Solid Tumors, NSCLC | I/II | NCT02285816 |
| 21 | LOAd703 | CD40L, 4-1BBL | Pancreatic cancer, bacillary cancer, collateral cancer | I/II | NCT03225989 |
| 22 | Ad-MAGEA3 | MAGE-A3 | NSCLC | I/II | NCT02879760 |
| 23 | Adv/tk (GMCI) | HSV-tk | Advanced non-metastatic pancreatic adenocarcinoma II | II | NCT02446093 |
| 24 | Ad5-SGE REIC/Dk3 (MTG201) | REIC/Dkk3 | Relapsed malignant pleural mesothelioma | II | 205 |
| 25 | Adv/HSV-tk | HSV-tk | Metastatic non-small cell lung carcinoma and uveal melanoma | II | NCT02831933 |
| 26 | DNX-2401 | Recurrent glioma | II | NCT02798406 | |
| 27 | Adv/tk | HSV-tk | Advanced hepatocellular carcinoma | III | 206 |
| 28 | rAd-IFN/Syn-3 (instiladrin) | INFα-2b | High grade non-muscle invasive bladder cancer | III | |
| 29 | Oncorine or H101 | head and neck cancer | III | 93, 109 | |
| 30 | Gendicine (rAd-p53) | P53 | head and neck squamous cell carcinoma, malignant glioma, HCC, NSCLC and epithelial ovarian carcinoma | III | 89–92 |